Appreciating the regulatory mechanisms underlying IL-33 biology is thus important for understanding inflammation.
Introduction
Interleukin-33 (IL-33) belongs to the IL-1 cytokine family, together with IL-1α, IL-1β and IL-18, and it plays central roles in parasitic infection and allergies [1] [2] [3] [4] . IL-33 was initially reported as a nuclear protein because of its constitutive expression in the nuclei of endothelial cells from high endo-thelial venules 5) . A series of studies has revealed that IL-33 is preferentially expressed by cells at the mucosal surface, including epithelial cells and smooth muscle cells 2, 4, 6) .
Although IL-33 is localized within nuclei and possesses transcriptional activities in vitro 7, 8) , it demonstrates powerful and broad effects when released into the extracellular environment. Release of IL-33 is caused by necrosis of damaged or infected tissue 9) or by extracellular danger signals such as ATP 10) and uric acid 11) . The IL-33 receptor consists of ST2, also called IL-1 receptor-like 1 (IL-1RL1),
T1, Der4 and fit-1, and IL-1 receptor accessory protein (IL1RAcP) 12, 13) . Binding of IL-33 to the receptor leads to rapid induction of T helper type 2 (Th2) immune responses 14) .
This system alerts the host to danger, for example tissue damage caused by pathogens. Therefore, IL-33 is often referred to as an "alarmin", together with IL-1α and high mobility group box chromosomal protein 1 (HMGB-1) 15) .
Accordingly, dysregulation of IL-33 localization within cells causes severe inflammation throughout the body 16) .
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. They cleave pro-IL-33 and remove the N-terminal domain, leaving the mature form of IL-33 with a ten-fold higher affinity to its receptor. The innate immune system therefore employs neutrophils to amplify local inflammation through extracellular regulation of IL-33.
Target cells of IL-33 in Th2 responses
IL-33 acts on a variety of cells including immune and non-immune cells 2, 6, 25) . 33, 34) and in mice 13, 35, 36) . IL-33
and IL-3 synergistically activate basophils to promote cytokine and chemokine production 31, 32, [37] [38] [39] [40] . Eosinophils isolated from human blood are also activated by IL-33 and
show increased survival and function 37, [41] [42] [43] . Polarization , which helps to recruit effector inflammatory cells. IL-33 therefore initiates Th2 responses in a variety of ways.
Role of IL-33 in allergy
A large number of investigations into IL-33 have focused on allergies and revealed that IL-33 is one of the most important cytokines associated with asthma 51, 52) , allergic rhinitis 53) and atopic dermatitis 54) . Upon allergen exposure, IL-33 is released by airway epithelial cells and activates a variety of cells as discussed above. Among them, ILC2s have pivotal roles during the early onset of allergic diseases [55] [56] [57] .
In response to IL-33, regional ILC2s located proximal to airway epithelial layers rapidly produce IL-5 and IL-13, resulting in eosinophil accumulation and mucus secretion, respectively 26, 28, 29) . In humans, ILC2s are also evident 58, 59) , and targeting IL-33 is thus of great interest in therapies for human allergic diseases. Several animal studies of asthma development examined the effects of blocking IL-33
signaling. Consistent with the study using IL-33-deficient mice 60) , both polyclonal anti-IL-33 antibodies 61) and anti-ST2 monoclonal antibodies 62) successfully reduced asthmatic symptoms in the animal models.
Emerging roles of IL-33
Recent advances in IL-33 research have led to puzzling results. Until recently, it had been believed that the major roles of IL-33 were to mediate Th2 responses in allergic reactions or against parasitic infection. Surprisingly, it has been found that IL-33 also plays roles in promoting Th1 immune responses 63) . IL-33 directly activates NK, NKT and CD8 + T cells and enhances the secretion of a Th1 cytokine, IFN-γ 32, 64, 65) . Moreover, IL-33/ST2 signaling is necessary to elicit cytotoxic CD8 + T cell responses for viral clearance 66) .
Taking advantage of the ability of IL-33 to promote the Th1 response, one report demonstrated its potential usage in a clinical application 67) . 44) . IL-33 employs ILC2s which provide
Th2 environment for differentiation of microphages into M2 macrophages 71) . They are known to reduce chronic inflammation which is thought to be one of the triggers for the development of obesity. Furthermore, IL-33 was shown to play a protective role in sepsis 72) . IL-33 treatment was demonstrated to contribute to bacterial clearance by enhancing neutrophil migration.
In contrast to the protective roles of IL-33, other studies suggest pathologic roles for IL-33 in inflammatory diseases.
IL-33 expression was increased in patients with rheumatoid
arthritis (RA) [73] [74] [75] [76] and animal models of RA demonstrated etiologic roles of IL-33 in its development 73, 74, [77] [78] [79] . Expression of IL-33 and ST2 was also upregulated in patients with systemic sclerosis 80) and subcutaneous administration of IL-33 in animals induced skin fibrosis 81) . Although the contribution of IL-33 to pathogenesis remains to be clarified, the IL-33/ST2 pathway appears to be associated with systemic lupus erythematosus 82, 83) and inflammatory bowel diseases 7, [84] [85] [86] in humans.
In addition, an intractable disease, pulmonary arterial hypertension (PAH), characterized by severe obstruction of small pulmonary arteries and concomitant high pulmonary artery pressure, seems to be associated with IL-33 because serum soluble ST2 levels are increased in PAH patients 87) .
Our data support the idea that IL-33 is an etiological factor for development of PAH. Previously, we generated an IL-5
reporter mouse and demonstrated that IL-33 enhanced IL-5 production from ILC2s, which lead to severe lung eosinophilia 29) . In unpublished experiments, IL-33 induced severe arterial hypertrophy in the lung, and the occurrence of the hypertrophy was largely dependent on IL-5 production from ILC2s. In line with this concept, IL-5 was reported to be involved in arterial hypertrophy in an animal model of PAH 88) . Other studies also indicated that Th2 responses trigger the development of PAH in ovalbumin-or house dust mite extract-induced PAH [89] [90] [91] . Furthermore, PAH is considered to be associated with schistosomiasis and experimental Schistosoma mansoni infection can induce arterial hypertrophy 92, 93) . In the schistosomiasis studies, Th2 cytokines, such as IL-4 and IL-13, or eosinophils, were suggested to be involved in PAH induction.
Taken many published results together, IL-33 is now known to be involved in a broad range of inflammatory diseases ( Fig. 2) and therefore a large number of investigations aim to block IL-33 signaling for therapies.
Concluding remarks
IL-33 is a multifunctional molecule that acts as a transcription factor, alarmin, Th1/Th2 promoter and chronic inflammatory factor. As there have been a number of reports that describe etiological roles of IL-33 in allergies and inflammatory diseases, blockade of IL-33/ST2 signaling is a promising new approach to therapeutic intervention 94, 95) .
However, we have to consider carefully how we manage 
